Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Echinaforce Chewable Tablets for Prevention of Enveloped Virus Infections
NCT05002179Phase 4Completed
- Sponsor
- A.Vogel
- Start
- Nov 2020
- Primary completion
- May 2021
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial (2 arms), sponsored by A.Vogel. Primary endpoint: Incidence of respiratory tract infections with treatment in comparison to no treatment at 5 months. Started Nov 2020; status: completed.
Beyond the preview
Go deeper on NCT05002179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05002179.